Skip to main content
. 2018 Jul 10;6(2):141–156. doi: 10.1007/s40487-018-0062-x

Table 2.

Assessment of responses (UICC)

Complete response (CR) No measurable disease
Partial response (PR) Reduction of at least 50% in maximal dimension
Objective response (OR) CR or PR
Stable disease (SD) No change
Progressive disease (PD) Increase of at least 25% in maximal dimension, or new disease
Clinical benefit (CB) OR + SD at or beyond 6 months
U/A Unassessable